DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Orthomyxoviridae are 426

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0028	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A(H1N1)pdm09		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0029	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A(H3N2)		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0030	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	B (Victoria lineage)		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0031	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	B (Yamagata lineage)		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0032	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A(H1N1)pdm09/A/Sydney/185/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0033	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A(H1N1)pdm09/A/Singapore/TT1275/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0034	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A(H1N1)pdm09/A/Sydney/158/2016		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0035	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A(H1N1)pdm09/A/Victoria/2500/2016		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0036	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A(H1N1)pdm09 /A/Malaysia/2/2014		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0037	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A(H3N2) /A/Victoria/1031/2010		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0038	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A(H3N2) /A/Victoria/1035/2010		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0039	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A(H3N2) /A/Victoria/92/2012		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0040	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A(H3N2) /A/Malaysia/22/2013		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0041	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A(H3N2) /A/Sydney/236/2014		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0042	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	B/ B/South Australia/2/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0043	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	B/ B/Canberra/1/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0044	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	B/ B/South Australia/5/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0045	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	B/ B/Perth/136/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_0270	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/New Jersey/15/2007		Relative fluorescent unit	Decrease (50 %)	Approved, Investigational	26833677
DrugRepV_0271	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Netherlands/026/2008		Relative fluorescent unit	Decrease (50 %)	Approved, Investigational	26833677
DrugRepV_0272	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Netherlands /049/2008		Relative fluorescent unit	No significant effect (50 %)	Approved, Investigational	26833677
DrugRepV_0273	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Brisbane/59/2007		Relative fluorescent unit	No significant effect (50 %)	Approved, Investigational	26833677
DrugRepV_0274	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/New Jersey/15/2007		Plaque assay	Decrease (10 %)	Approved, Investigational	26833677
DrugRepV_0275	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Brisbane/59/2007		Plaque assay	No significant effect	Approved, Investigational	26833677
DrugRepV_0276	Dorzolamide	Sensory Organ	Open-angle glaucoma and ocular hypertension	Influenza virus	A/New Jersey/15/2007		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0277	Dorzolamide	Sensory Organ	Open-angle glaucoma and ocular hypertension	Influenza virus	A/Netherlands/026/2008		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0278	Dorzolamide	Sensory Organ	Open-angle glaucoma and ocular hypertension	Influenza virus	A/Netherlands /049/2008		Relative fluorescent unit	No significant effect (50 %)	Approved	26833677
DrugRepV_0279	Dorzolamide	Sensory Organ	Open-angle glaucoma and ocular hypertension	Influenza virus	A/Brisbane/59/2007		Relative fluorescent unit	No significant effect (50 %)	Approved	26833677
DrugRepV_0280	Dorzolamide	Sensory Organ	Open-angle glaucoma and ocular hypertension	Influenza virus	A/New Jersey/15/2007		Plaque assay	Decrease (10 %)	Approved	26833677
DrugRepV_0281	Dorzolamide	Sensory Organ	Open-angle glaucoma and ocular hypertension	Influenza virus	A/Brisbane/59/2007		Plaque assay	No significant effect (NA %)	Approved	26833677
DrugRepV_0282	Diclofenac	Dermatologicals; Musculo-Skeletal System and Sensory Organ	Fever and pain	Influenza virus	A/New Jersey/15/2007		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0283	Diclofenac	Dermatologicals; Musculo-Skeletal System and Sensory Organ	Fever and pain	Influenza virus	A/Netherlands/026/2008		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0284	Diclofenac	Dermatologicals; Musculo-Skeletal System and Sensory Organ	Fever and pain	Influenza virus	A/Netherlands /049/2008		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0285	Diclofenac	Dermatologicals; Musculo-Skeletal System and Sensory Organ	Fever and pain	Influenza virus	A/Brisbane /56/2007		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0286	Imipenem	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/New Jersey/15/2007		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0287	Imipenem	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Netherlands/026/2008		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0288	Imipenem	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Netherlands /049/2008		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0289	Imipenem	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Brisbane /56/2007		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0296	Dinaciclib	Anticancer	Cancer	Influenza virus	A/Anhui/1/ 2013		Immunoflourescence assay	Decrease (50 %)	Investigational	26192013
DrugRepV_0297	Dinaciclib	Anticancer	Cancer	Influenza virus	A/California/04/09		Immunoflourescence assay	Decrease (50 %)	Investigational	26192013
DrugRepV_0298	Dinaciclib	Anticancer	Cancer	Influenza virus	A/Philippines/2/82-X79		Immunoflourescence assay	Decrease (50 %)	Investigational	26192013
DrugRepV_0299	Flavopiridol	Anticancer	Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer	Influenza virus	A/Anhui/1/ 2013		Immunoflourescence assay	Decrease (50 %)	Experimental, Investigational	26192013
DrugRepV_0300	Flavopiridol	Anticancer	Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer	Influenza virus	A/California/04/09		Immunoflourescence assay	Decrease (50 %)	Experimental, Investigational	26192013
DrugRepV_0301	Flavopiridol	Anticancer	Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer	Influenza virus	A/Philippines/2/82-X79		Immunoflourescence assay	Decrease (50 %)	Experimental, Investigational	26192013
DrugRepV_0302	PIK-75	NA	NA	Influenza virus	A/Anhui/1/ 2013		Immunoflourescence assay	Decrease (50 %)	NA	26192013
DrugRepV_0303	PIK-75	NA	NA	Influenza virus	A/California/04/09		Immunoflourescence assay	Decrease (50 %)	NA	26192013
DrugRepV_0304	PIK-75	NA	NA	Influenza virus	A/Philippines/2/82-X79		Immunoflourescence assay	Decrease (50 %)	NA	26192013
DrugRepV_0305	Dinaciclib	Anticancer	Cancer	Influenza virus	A/Mississippi/3/01 wt		TCID50 assay	Decrease (1.5 Log10 virus titer (TCID50/ml))	Investigational	26192013
DrugRepV_0306	Dinaciclib	Anticancer	Cancer	Influenza virus	A/Mississippi/3/01 H275Y		TCID50 assay	Decrease (>1 Log10 virus titer (TCID50/ml))	Investigational	26192013
DrugRepV_0307	Flavopiridol	Anticancer	Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer	Influenza virus	A/Mississippi/3/01 wt		TCID50 assay	Decrease (1.5 Log10 virus titer (TCID50/ml))	Experimental, Investigational	26192013
DrugRepV_0308	Flavopiridol	Anticancer	Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer	Influenza virus	A/Mississippi/3/01 H275Y		TCID50 assay	Decrease (~1 Log10 virus titer (TCID50/ml))	Experimental, Investigational	26192013
DrugRepV_0309	PIK-75	NA	NA	Influenza virus	A/Mississippi/3/01 wt		TCID50 assay	Decrease (~1 Log10 virus titer (TCID50/ml))	NA	26192013
DrugRepV_0310	PIK-75	NA	NA	Influenza virus	A/Mississippi/3/01 H275Y		TCID50 assay	Decrease (~1 Log10 virus titer (TCID50/ml))	NA	26192013
DrugRepV_0311	Dinaciclib	Anticancer	Cancer	Influenza virus	A/Mississippi/3/01 wt		Immunoflourescence assay	Decrease (>95 %)	Investigational	26192013
DrugRepV_0312	Dinaciclib	Anticancer	Cancer	Influenza virus	A/Mississippi/3/01 H275Y		Immunoflourescence assay	Decrease (95 %)	Investigational	26192013
DrugRepV_0313	Flavopiridol	Anticancer	Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer	Influenza virus	A/Mississippi/3/01 wt		Immunoflourescence assay	Decrease (>95 %)	Experimental, Investigational	26192013
DrugRepV_0314	Flavopiridol	Anticancer	Esophageal cancer | Leukemia (lymphoid) | Lung cancer | Liver cancer	Influenza virus	A/Mississippi/3/01 H275Y		Immunoflourescence assay	Decrease (90 %)	Experimental, Investigational	26192013
DrugRepV_0315	PIK-75	NA	NA	Influenza virus	A/Mississippi/3/01 wt		Immunoflourescence assay	Decrease (90 %)	NA	26192013
DrugRepV_0316	PIK-75	NA	NA	Influenza virus	A/Mississippi/3/01 H275Y		Immunoflourescence assay	Decrease (85 %)	NA	26192013
DrugRepV_0580	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Influenza virus	Anhui01		Plaque assay	Decrease (1.3 Log10 copies)	Approved, Investigational	24496798
DrugRepV_0732	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/WSN/33		Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	23129053
DrugRepV_0733	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/WSN/33		Fluorescence-based assay	Decrease (3 Fold)	Approved, Investigational	23129053
DrugRepV_0734	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/New/ Caledonia/20/99		Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	23129053
DrugRepV_0735	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/California/07/09		Fluorescence-based assay	Decrease (25 %)	Approved, Investigational	23129053
DrugRepV_0736	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/Philippines/2/82/X-79		Fluorescence-based assay	Decrease (15 %)	Approved, Investigational	23129053
DrugRepV_0737	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/WSN/33		Real-time PCR	Decrease (>4 Fold)	Approved, Investigational	23129053
DrugRepV_0738	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/New/ Caledonia/20/99		Real-time PCR	Decrease (~10 Fold)	Approved, Investigational	23129053
DrugRepV_0739	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/California/04/09		Real-time PCR	Decrease (2 Fold)	Approved, Investigational	23129053
DrugRepV_0740	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/WSN/33		TCID50 assay	Decrease (>3 Log10 TCID50)	Approved, Investigational	23129053
DrugRepV_0741	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/New/ Caledonia/20/99		TCID50 assay	Decrease (2 Log10 TCID50)	Approved, Investigational	23129053
DrugRepV_0742	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/California/04/09		TCID50 assay	Decrease (>1 Log10 TCID50)	Approved, Investigational	23129053
DrugRepV_0743	Probenecid	Musculo-Skeletal System	Gout	Influenza virus	A/WSN/33		NA	Increase	Approved, Investigational	23129053
DrugRepV_1619	Warfarin	Blood and Blood Forming Organs	Coagulation disorders	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Approved	24991006
DrugRepV_1620	Palmitoylethanolamide	Antiviral	Respiratory viral infection	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Experimental	24991006
DrugRepV_1621	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Approved, Investigational, Vet approved	24991006
DrugRepV_1622	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Approved, Investigational	24991006
DrugRepV_1623	Lavendustin A	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1624	Imidapril	Cardiovascular agents	Autosomal dominant polycystic kidney disease (ADPKD)	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Investigational	24991006
DrugRepV_1625	Glyburide	Alimentary Tract and Metabolism	Type 2 Diabetes Mellitus	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Approved	24991006
DrugRepV_1626	Etalocib	Anticancer	Cancer	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Investigational	24991006
DrugRepV_1627	Dobutamine	Cardiovascular agents	Myocardial infarction	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Approved	24991006
DrugRepV_1628	D-serine	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Approved	24991006
DrugRepV_1629	Carteolol	Cardiovascular agents	Anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Approved	24991006
DrugRepV_1630	Candesartan cilexetil	Cardiovascular agents	Hypertension	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Approved	24991006
DrugRepV_1631	Eptifibatide	Blood and Blood Forming Organs	Myocardial infarction	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Approved	24991006
DrugRepV_1632	2,2-Dipyridyl Disulfide	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Experimental	24991006
DrugRepV_1633	Etalocib	Anticancer	Cancer	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Investigational	24991006
DrugRepV_1634	Veratridine	Plant extract	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1635	Pobilukast	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1636	PD-180970	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1637	Methylanthraniloyl guanosine triphosphate	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1638	Mastoparan	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1639	Hexadimethrine Bromide	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1640	Dideooxyforskolin	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1641	Compound 48/80	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1642	3-(N-methylanthraniloyl)-2-deoxy-ATP	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1643	3-Aminotriazole	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1644	2/3-O-N-methyanthraniloyl-ITP-gamma-S	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1645	2/3-O-N-methyanthraniloyl-GTP-gamma-S	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1646	2-(or3)-O-(N-methylanthranioyl)ATP	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1647	2-Aminopurine	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1648	1-cyclopropyl-3	NA	NA	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	NA	24991006
DrugRepV_1925	Manidipine	Cardiovascular agents	Hypertension	Influenza virus	PR/8/34		Plaque assay	No significant effect (50 %)	Approved, Investigational	29274844
DrugRepV_1965	Fenretinide-Butylated Hydroxyanisole	NA	NA	Influenza virus	Strain A/PR8/ 34		Plaque assay	No significant effect	Investigational	25313218
DrugRepV_3181	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3182	Arbidol	NA	Viral infection	Influenza virus	B/Beijing/184/93		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3183	Arbidol	NA	Viral infection	Influenza virus	A/Mem Bel		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3184	Arbidol	NA	Viral infection	Influenza virus	A/Queensland/6/72		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3185	Arbidol	NA	Viral infection	Influenza virus	A/Sydney/5/ 97		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3186	Arbidol	NA	Viral infection	Influenza virus	A/Moscow/16/98		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3187	Arbidol	NA	Viral infection	Influenza virus	A/PR/8/34		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3188	Arbidol	NA	Viral infection	Influenza virus	A/Moscow/17/98		Plaque assay	Decrease (50 %)	Investigational	22028179
DrugRepV_3189	Amantadine	Nervous System	Influenza and Parkinson Disease	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (50 %)	Approved	22028179
DrugRepV_3190	Rimantadine	Antiinfectives For Systemic Use	Influenza A virus	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (50 %)	Approved, Investigational	22028179
DrugRepV_3191	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (Decrease (0.5-1.0) log)	Investigational	22028179
DrugRepV_3192	Amantadine	Nervous System	Influenza and Parkinson Disease	Influenza virus	A/Aichi/2/68		Plaque assay	No significant reduction (No significant reduction log)	Approved	22028179
DrugRepV_3193	Rimantadine	Antiinfectives For Systemic Use	Influenza A virus	Influenza virus	A/Aichi/2/68		Plaque assay	No significant reduction (No significant reduction log)	Approved, Investigational	22028179
DrugRepV_3194	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Quantal assay	Decrease (1.5 log)	Investigational	22028179
DrugRepV_3195	Amantadine	Nervous System	Influenza and Parkinson Disease	Influenza virus	A/Aichi/2/68		Quantal assay	No significant reduction (No significant reduction log)	Approved	22028179
DrugRepV_3196	Rimantadine	Antiinfectives For Systemic Use	Influenza A virus	Influenza virus	A/Aichi/2/68		Quantal assay	Decrease (1 log)	Approved, Investigational	22028179
DrugRepV_3197	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (2.5 log)	Investigational	22028179
DrugRepV_3198	Arbidol	NA	Viral infection	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (3.73 log)	Investigational	22028179
DrugRepV_3293	5-Tetradecyloxy-2-furoic Acid	NA	NA	Influenza virus	NA		Flow cytometry	Decrease (100 %)	NA	27177310
DrugRepV_3294	Cerulenin	NA	Fungal infection	Influenza virus	NA		Flow cytometry	Decrease (100 %)	Approved	27177310
DrugRepV_3295	Bafilomycin	Antibiotics	Bacterial infection	Influenza virus	NA		Flow cytometry	Decrease (100 %)	Experimental	27177310
DrugRepV_3296	Pimozide	Nervous System	Tourette Disorder	Influenza virus	NA		Flow cytometry	Decrease (100 %)	Approved	27177310
DrugRepV_3297	TIvozanib	NA	Solid Tumors, Glioblastoma, Ovarian Cancer, Prostate Cancer, and Stage IV Disease	Influenza virus	NA		Flow cytometry	Decrease (100 %)	Investigational	27177310
DrugRepV_3317	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Cryptosporidiosis and Giardiasis	Influenza virus	B/Brisbane/46/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_3318	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Cryptosporidiosis and Giardiasis	Influenza virus	B/Sydney/39/2014		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_3319	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Cryptosporidiosis and Giardiasis	Influenza virus	A/Perth/265/2009		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_3320	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Cryptosporidiosis and Giardiasis	Influenza virus	A/Osaka/180/2009		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_3321	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Cryptosporidiosis and Giardiasis	Influenza virus	A/New Caledonia/104/2014		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_3322	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Cryptosporidiosis and Giardiasis	Influenza virus	A/Newcastle/22/2014		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_3323	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Influenza virus	A/WSN/33		MTT assay	Decrease (50 %)	Approved	23459490
DrugRepV_3324	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Influenza virus	A/WSN/33		Plaque assay	Decrease (50 %)	Approved	23459490
DrugRepV_3325	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Influenza virus	A/WSN/33		Real-time PCR	Decrease (50 %)	Approved	23459490
DrugRepV_3326	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Influenza virus	A/WSN/33		Plaque assay	Decrease (2.5 Log)	Approved	23459490
DrugRepV_3327	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Influenza virus	UDORN/72		Plaque assay	Decrease (2.5 Log)	Approved	23459490
DrugRepV_3328	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Influenza virus	A/PR8		Plaque assay	Decrease (1.5 Log)	Approved	23459490
DrugRepV_3329	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	WSN/H1N1		Plaque assay	Decrease (99 %)	Approved	29990517
DrugRepV_3330	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	FPV/H7N7		Plaque assay	Decrease (99 %)	Approved	29990517
DrugRepV_3331	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	RB1/H1N1pdm09		Plaque assay	Decrease (50 %)	Approved	29990517
DrugRepV_3332	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	PR8M/H1N1		Plaque assay	No significant effect (0.3 Log)	Approved	29990517
DrugRepV_3333	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	Victoria/H3N2		Plaque assay	Decrease (1.2 Log)	Approved	29990517
DrugRepV_3334	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	FPV/H7N7		Plaque assay	Decrease (1 Log)	Approved	29990517
DrugRepV_3335	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	WSN/H1N1		Plaque assay	Decrease (98 %)	Approved	29990517
DrugRepV_3336	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	Victoria/H3N2		Plaque assay	Decrease (76 %)	Approved	29990517
DrugRepV_3337	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	FPV/H7N7		Plaque assay	Decrease (80 %)	Approved	29990517
DrugRepV_3338	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	WSN/H1N1		Plaque assay	No significant effect (0.8 Log)	Approved	29990517
DrugRepV_3339	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	WSN/H1N1		Plaque assay	Decrease (70 %)	Approved	29990517
DrugRepV_3340	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	Victoria/H3N2		Plaque assay	Decrease (70 %)	Approved	29990517
DrugRepV_3341	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	FPV/H7N7		Plaque assay	Decrease (100 %)	Approved	29990517
DrugRepV_3342	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	WSN/H1N1		Plaque assay	No significant effect (0.8 Log)	Approved	29990517
DrugRepV_3343	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	Victoria/H3N2		Plaque assay	No significant effect (0.5 Log)	Approved	29990517
DrugRepV_3344	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	KAN-1/H5N1		Plaque assay	Decrease (98 %)	Approved	29990517
DrugRepV_3345	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	Mallard/H5N1		Plaque assay	Decrease (99 %)	Approved	29990517
DrugRepV_3346	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	SC35M/H7N7		Plaque assay	Decrease (90 %)	Approved	29990517
DrugRepV_3347	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	KAN-1/H5N1		Plaque assay	Decrease (1.2 Log)	Approved	29990517
DrugRepV_3348	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	SC35M/H7N7		Plaque assay	No significant effect (0.8 Log)	Approved	29990517
DrugRepV_3349	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	WSN/H1N1		Plaque assay	No significant effect (40 %)	Approved	29990517
DrugRepV_3350	Trametinib-Oseltamivir	NA	NA	Influenza virus	WSN/H1N1		Plaque assay	Decrease (95 %)	Approved	29990517
DrugRepV_3351	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	WSN/H1N1		Plaque assay	Decrease (1.5 Log)	Approved	29990517
DrugRepV_3352	Trametinib-Oseltamivir	NA	NA	Influenza virus	WSN/H1N1		Plaque assay	Decrease (3.5 Log)	Approved	29990517
DrugRepV_3353	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	RB1/H1N1pdm09		Plaque assay	Decrease (1.5 Log)	Approved	29990517
DrugRepV_3354	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	RB1/H1N1pdm09		Plaque assay	Decrease (98 %)	Approved	29990517
DrugRepV_3355	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	RB1/H1N1pdm09		Survival assay	Decrease	Approved	29990517
DrugRepV_3356	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Influenza virus	A/WSN/33		Cell viability assay	Decrease (50 %)	Approved	30028133
DrugRepV_3357	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Influenza virus	A/Udorn/72		Plaque assay	Decrease (50 %)	Approved	30028133
DrugRepV_3358	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Influenza virus	A/Udorn/72		Cell viability assay	Decrease (50 %)	Approved	30028133
DrugRepV_3359	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Influenza virus	A/PR/8/34		Survival assay	Increase	Approved	30028133
DrugRepV_3360	Naproxen	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Ankylosing spondylitis | Polyarticular juvenile idiopathic arthritis | Tendinitis | Bursitis | Acute gout | Primary dysmenorrhea	Influenza virus	A/PR/8/34		Plaque assay	No significant effect (0.5 Log)	Approved	30028133
DrugRepV_3365	Mycophenolic Acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Influenza virus	A/ WSN/1933 (H1N1)		High-throughput screening	Decrease (50 %)	Approved	24096239
DrugRepV_3366	Flufenamic Acid	Musculo-Skeletal System	Musculoskeletal | Joint disorders	Influenza virus	A/ WSN/1933 (H1N1)		High-throughput screening	Decrease (50 %)	Approved	24096239
DrugRepV_3367	Tolfenamic Acid	Musculo-Skeletal System	Pain associated with the acute attack of migraines	Influenza virus	A/ WSN/1933 (H1N1)		High-throughput screening	Decrease (50 %)	Approved, Investigational	24096239
DrugRepV_3368	Mefenamic Acid	Musculo-Skeletal System	Rheumatoid arthritis | Osteoarthritis | Dysmenorrhea, and mild to moderate pain, inflammation, and fever	Influenza virus	A/ WSN/1933 (H1N1)		High-throughput screening	Decrease (50 %)	Approved	24096239
DrugRepV_3369	Meclofenamate sodium	Musculo-Skeletal System	Pain | Primary dysmenorrhea	Influenza virus	A/ WSN/1933 (H1N1)		High-throughput screening	Decrease (50 %)	Approved, Vet approved	24096239
DrugRepV_3370	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Influenza virus	A/ WSN/1933 (H1N1)		High-throughput screening	Decrease (50 %)	Approved	24096239
DrugRepV_3371	Mercaptopurine	Antineoplastic and Immunomodulating Agents	Acute lymphatic leukemia	Influenza virus	A/ WSN/1933 (H1N1)		High-throughput screening	Decrease (50 %)	Approved	24096239
DrugRepV_3372	Pyrimethamine	Antiparasitic products, Insectisides and Repellents	Toxoplasmosis | Acute malaria	Influenza virus	A/ WSN/1933 (H1N1)		High-throughput screening	Decrease (50 %)	Approved, Investigational, Vet approved	24096239
DrugRepV_3373	Emetine	Antiparasitic products, Insectisides and Repellents	Protozoal disease	Influenza virus	A/ WSN/1933 (H1N1)		High-throughput screening	Decrease (50 %)	Experimental	24096239
DrugRepV_3374	Estradiol	Genito Urinary System and Sex Hormones	Vulvar and vaginal atrophy	Influenza virus	A/ WSN/1933 (H1N1)		High-throughput screening	Decrease (50 %)	Approved	24096239
DrugRepV_3409	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3410	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3411	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3412	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3413	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	B/Bris/60/2008 (Victoria)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3414	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Influenza virus	B/Bris/60/2008 (Victoria)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3415	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	B/Bris/60/2008 (Victoria)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3416	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/7/2009 (H1N1)		Plaque assay	Decrease (2.1 Log)	Investigational	28778830
DrugRepV_3417	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/7/2009 (H1N1)		Plaque assay	Decrease (2.9 Log)	Investigational	28778830
DrugRepV_3418	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	A/California/7/2009 (H1N1)		Plaque assay	Decrease (1.7 Log)	Approved	28778830
DrugRepV_3419	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	A/California/7/2009 (H1N1)		Plaque assay	Decrease (2 Log)	Approved	28778830
DrugRepV_3420	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/WSN/1933 (H1N1)		Plaque assay	Decrease (1.7 Log)	Investigational	28778830
DrugRepV_3421	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	A/WSN/1933 (H1N1)		Plaque assay	Decrease (1.4 Log)	Approved	28778830
DrugRepV_3422	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/DM/528/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3423	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Texas/4/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3424	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/North Carolina/39/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3425	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Washington/29/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3426	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/WSN/1933 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3427	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3428	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/DM/524/2009 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3429	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Switzerland/9715293/2013 (H3N2)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3430	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Switzerland/9715293/2013 X-247 (H3N2)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3431	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Hongkong/4801/2014 (H3N2)		Cytopathic effect (CPE) assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3432	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/California/2/2014 (H3N2)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3433	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Udorn/1972 (H3N2)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3434	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	A/Soloman Islands/3/2006 (H1N1)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3435	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	B/Wisconsin/1/2010 (Yamagata)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3436	Dapivirine	NA	Acquired immunodeficiency syndrome	Influenza virus	B/Bris/60/2008 (Victoria)		Plaque assay	Decrease (50 %)	Investigational	28778830
DrugRepV_3437	Obatoclax	Anticancer	Leukemia | Myelofibrosis | Hodgkin's Lymphoma | Mantle-Cell Lymphoma	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Investigational	22910914
DrugRepV_3438	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Approved	22910914
DrugRepV_3439	Saliphenylhalamide	NA	NA	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	NA	22910914
DrugRepV_3440	Carfilzomib	Antineoplastic and Immunomodulating Agents	Multiple myeloma	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Approved	22910914
DrugRepV_3441	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple myeloma and mantle cell lymphoma	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Approved	22910914
DrugRepV_3442	NVP-AUY922	NA	NA	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	NA	22910914
DrugRepV_3443	Alvespimycin	NA	Cancer	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Investigational	22910914
DrugRepV_3444	Tanespimycin	NA	Cancer	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Investigational	22910914
DrugRepV_3445	Obatoclax	Anticancer	Leukemia | Myelofibrosis | Hodgkin's Lymphoma | Mantle-Cell Lymphoma	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Investigational	22910914
DrugRepV_3446	Gemcitabine	Antineoplastic and Immunomodulating Agents	Ovarian cancer | Non-small cell lung cance | Adenocarcinoma of the pancreas	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Approved	22910914
DrugRepV_3447	Saliphenylhalamide	NA	NA	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	NA	22910914
DrugRepV_3448	Carfilzomib	Antineoplastic and Immunomodulating Agents	Multiple myeloma	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Approved	22910914
DrugRepV_3449	Bortezomib	Antineoplastic and Immunomodulating Agents	Multiple myeloma and mantle cell lymphoma	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Approved	22910914
DrugRepV_3450	NVP-AUY922	NA	NA	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	NA	22910914
DrugRepV_3451	Alvespimycin	NA	Cancer	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Investigational	22910914
DrugRepV_3452	Tanespimycin	NA	Cancer	Influenza virus	PR8-GFP		GFP assay	Decrease (50 %)	Investigational	22910914
DrugRepV_3453	Zanamivir-Flufenamic Acid	Combinational	NA	Influenza virus	pdm09		Cell proliferation assay	Decrease (50 %)	NA	29736671
DrugRepV_3454	Zanamivir-Clarithromycin	Combinational	NA	Influenza virus	pdm09		Cell proliferation assay	Decrease (50 %)	NA	29736671
DrugRepV_3455	Zanamivir-Flufenamic Acid-Clarithromycin	Combinational	NA	Influenza virus	pdm09		Cell proliferation assay	Decrease (50 %)	NA	29736671
DrugRepV_3456	Zanamivir-Clarithromycin	Combinational	NA	Influenza virus	pdm09		Survival assay	Increase	NA	29736671
DrugRepV_3457	Zanamivir-Flufenamic Acid-Clarithromycin	Combinational	NA	Influenza virus	pdm09		Survival assay	Increase	NA	29736671
DrugRepV_3458	Hesperadin	Anticancer	NA	Influenza virus	A/Texas/4/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3459	Hesperadin	Anticancer	NA	Influenza virus	A/North Carolina/39/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3460	Hesperadin	Anticancer	NA	Influenza virus	A/Washington/29/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3461	Hesperadin	Anticancer	NA	Influenza virus	A/California/02/2014 (H3N2)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3462	Hesperadin	Anticancer	NA	Influenza virus	A/Texas/12/2007 (H3N2)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3463	Hesperadin	Anticancer	NA	Influenza virus	A/WSN/1933 (H1N1)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3464	Hesperadin	Anticancer	NA	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3465	Hesperadin	Anticancer	NA	Influenza virus	B/Wisconsin/1/2010 (Yamagata)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3466	Hesperadin	Anticancer	NA	Influenza virus	B/brisbane/60/2008 (victoria)		Plaque assay	Decrease (50 %)	Approved, Investigational	28885544
DrugRepV_3467	Hesperadin	Anticancer	NA	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (2.5 Log)	Approved, Investigational	28885544
DrugRepV_3468	Hesperadin	Anticancer	NA	Influenza virus	A/Washington/39/2009 (H1N1)		Plaque assay	Decrease (2.5 Log)	Approved, Investigational	28885544
DrugRepV_3469	Hesperadin	Anticancer	NA	Influenza virus	B/Wisconsin/1/2010 (Yamagata)		Plaque assay	Decrease (3.4 Log)	Approved, Investigational	28885544
DrugRepV_3470	Pyrrolopyridinamine PPA-7	NA	NA	Influenza virus	CA/09 (H1N1)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3471	Aminothiadiazole ATD-1	NA	NA	Influenza virus	CA/09 (H1N1)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3472	Dihydrofuropyridine carboxamide HPC-2	NA	NA	Influenza virus	CA/09 (H1N1)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3473	Pyrrolopyridinamine PPA-7	NA	NA	Influenza virus	PE/09 (H3N2)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3474	Aminothiadiazole ATD-1	NA	NA	Influenza virus	PE/09 (H3N2)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3475	Dihydrofuropyridine carboxamide HPC-2	NA	NA	Influenza virus	PE/09 (H3N2)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3476	Pyrrolopyridinamine PPA-7	NA	NA	Influenza virus	B/Florida/04/2006 (B/FL/06)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3477	Aminothiadiazole ATD-1	NA	NA	Influenza virus	B/Florida/04/2006 (B/FL/06)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3478	Dihydrofuropyridine carboxamide HPC-2	NA	NA	Influenza virus	B/Florida/04/2006 (B/FL/06)		Immunoflourescence assay	Decrease (50 %)	NA	27586275
DrugRepV_3479	Pyrrolopyridinamine PPA-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3480	Pyrrolopyridinamine PPA-2	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3481	Pyrrolopyridinamine PPA-3	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3482	Pyrrolopyridinamine PPA-4	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3483	Pyrrolopyridinamine PPA-5	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3484	Pyrrolopyridinamine PPA-6	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3485	Pyrrolopyridinamine PPA-7	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3486	Pyrrolopyridinamine PPA-8	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3487	Pyrrolopyridinamine PPA-9	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3488	Pyrrolopyridinamine PPA-10	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3489	Pyrrolopyridinamine PPA-11	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3490	Pyrrolopyridinamine PPA-12	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3491	Pyrrolopyridinamine PPA-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3492	Pyrrolopyridinamine PPA-2	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3493	Pyrrolopyridinamine PPA-3	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3494	Pyrrolopyridinamine PPA-4	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3495	Pyrrolopyridinamine PPA-5	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3496	Pyrrolopyridinamine PPA-6	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3497	Pyrrolopyridinamine PPA-7	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3498	Pyrrolopyridinamine PPA-8	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3499	Pyrrolopyridinamine PPA-9	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3500	Pyrrolopyridinamine PPA-10	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3501	Pyrrolopyridinamine PPA-11	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3502	Pyrrolopyridinamine PPA-12	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3503	Aminothiadiazole ATD-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3504	Aminothiadiazole ATD-2	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3505	Aminothiadiazole ATD-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3506	Aminothiadiazole ATD-2	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3507	Dihydrofuropyridine carboxamide HPC-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3508	Dihydrofuropyridine carboxamide HPC-2	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3509	Dihydrofuropyridine carboxamide HPC-3	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3510	Dihydrofuropyridine carboxamide HPC-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3511	Dihydrofuropyridine carboxamide HPC-2	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3512	Dihydrofuropyridine carboxamide HPC-3	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3513	Imidazopyridinamine IPA-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3514	Imidazopyridinamine IPA-1	NA	NA	Influenza virus	A/Puerto Rico/8/1934 virus (NS1-GFP virus)		PR8GFP Assay	Decrease (50 %)	NA	27586275
DrugRepV_3515	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A/Ohio/88/2012		Virus yield reduction assay	Decrease (90 %)	Approved, Investigational, Vet approved	24449767
DrugRepV_3516	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A/Ohio/83/2012		Virus yield reduction assay	Decrease (90 %)	Approved, Investigational, Vet approved	24449767
DrugRepV_3517	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A/Washington/01/2007		Virus yield reduction assay	Decrease (90 %)	Approved, Investigational, Vet approved	24449767
DrugRepV_3518	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A/Texas/12/2007		Virus yield reduction assay	Decrease (90 %)	Approved, Investigational, Vet approved	24449767
DrugRepV_3519	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	Influenza virus	A/California/04/2009		Virus yield reduction assay	Decrease (90 %)	Approved, Investigational, Vet approved	24449767
DrugRepV_3520	Favipiravir	Antiviral	Influenza virus	Influenza virus	A/Ohio/88/2012		Virus yield reduction assay	Decrease (90 %)	Investigational	24449767
DrugRepV_3521	Favipiravir	Antiviral	Influenza virus	Influenza virus	A/Ohio/83/2012		Virus yield reduction assay	Decrease (90 %)	Investigational	24449767
DrugRepV_3522	Favipiravir	Antiviral	Influenza virus	Influenza virus	A/Washington/01/2007		Virus yield reduction assay	Decrease (90 %)	Investigational	24449767
DrugRepV_3523	Favipiravir	Antiviral	Influenza virus	Influenza virus	A/Texas/12/2007		Virus yield reduction assay	Decrease (90 %)	Investigational	24449767
DrugRepV_3524	Favipiravir	Antiviral	Influenza virus	Influenza virus	A/California/04/2009		Virus yield reduction assay	Decrease (90 %)	Investigational	24449767
DrugRepV_3525	Fludase	Antiviral	Asthma and Bronchiectasis	Influenza virus	A/Ohio/88/2012		Virus yield reduction assay	Decrease (90 %)	Phase I	24449767
DrugRepV_3526	Fludase	Antiviral	Asthma and Bronchiectasis	Influenza virus	A/Ohio/83/2012		Virus yield reduction assay	Decrease (90 %)	Phase I	24449767
DrugRepV_3527	Fludase	Antiviral	Asthma and Bronchiectasis	Influenza virus	A/Washington/01/2007		Virus yield reduction assay	Decrease (90 %)	Phase I	24449767
DrugRepV_3528	Fludase	Antiviral	Asthma and Bronchiectasis	Influenza virus	A/Texas/12/2007		Virus yield reduction assay	Decrease (90 %)	Phase I	24449767
DrugRepV_3529	Fludase	Antiviral	Asthma and Bronchiectasis	Influenza virus	A/California/04/2009		Virus yield reduction assay	Decrease (90 %)	Phase I	24449767
DrugRepV_3530	Carbinoxamine maleate	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Influenza virus	A/Puerto Rico/8/1934(H1N1)		CPE reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3531	Carbinoxamine maleate	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Influenza virus	A/Guizhou/54/1989(H3N2)		CPE reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3532	Carbinoxamine maleate	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Influenza virus	A/Shanghai/37T/2009(H1N1)		CPE reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3533	Carbinoxamine maleate	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Influenza virus	B/Shanghai/2017(BY)		CPE reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3534	Carbinoxamine maleate	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Influenza virus	A/H7N9/4664T/2013 (H7N9)		CPE reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3535	Chlorpheniramine Maleate	Respiratory System	Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma	Influenza virus	A/Puerto Rico/8/1934(H1N1)		CPE reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3536	Chlorpheniramine Maleate	Respiratory System	Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma	Influenza virus	A/Guizhou/54/1989(H3N2)		CPE reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3537	Chlorpheniramine Maleate	Respiratory System	Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma	Influenza virus	A/Shanghai/37T/2009(H1N1)		CPE reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3538	Chlorpheniramine Maleate	Respiratory System	Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma	Influenza virus	B/Shanghai/2017(BY)		CPE reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3539	Chlorpheniramine Maleate	Respiratory System	Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma	Influenza virus	A/H7N9/4664T/2013 (H7N9)		CPE reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3540	Carbinoxamine maleate	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Influenza virus	A/Shanghai/37T/2009(H1N1)		Plaque reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3541	Carbinoxamine maleate	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Influenza virus	A/Guizhou/54/1989(H3N2)		Plaque reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3542	Chlorpheniramine Maleate	Respiratory System	Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma	Influenza virus	A/Shanghai/37T/2009(H1N1)		Plaque reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3543	Chlorpheniramine Maleate	Respiratory System	Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma	Influenza virus	A/Guizhou/54/1989(H3N2)		Plaque reduction assay	Decrease (50 %)	Approved	30459739
DrugRepV_3544	Carbinoxamine maleate	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Influenza virus	A/PR/8/1934 (H1N1)		Real-time PCR	Decrease (90 %)	Approved	30459739
DrugRepV_3545	Chlorpheniramine Maleate	Respiratory System	Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma	Influenza virus	A/PR/8/1934 (H1N1)		Real-time PCR	Decrease (80 %)	Approved	30459739
DrugRepV_3546	Carbinoxamine maleate	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Influenza virus	A/PR/8/1934 (H1N1)		Indirect immunofluorescence assay	Decrease	Approved	30459739
DrugRepV_3547	Chlorpheniramine Maleate	Respiratory System	Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma	Influenza virus	A/PR/8/1934 (H1N1)		Indirect immunofluorescence assay	Decrease	Approved	30459739
DrugRepV_3548	Carbinoxamine maleate	Respiratory System	Allergic rhinitis, vasomotor rhinitis and allergic conjunctivitis	Influenza virus	A/Shanghai/4664T/2013(H7N9)		Survival assay	Increase	Approved	30459739
DrugRepV_3549	Chlorpheniramine Maleate	Respiratory System	Allergic reactions | Hay fever | Rhinitis | Urticaria | Asthma	Influenza virus	A/Shanghai/4664T/2013(H7N9)		Survival assay	Increase	Approved	30459739
DrugRepV_3610	Gliotoxin	NA	NA	Influenza virus	A/ swine/Rachaburi/2000 (H1N1)		Taqman PCR	Decrease (50 %)	NA	19889218
DrugRepV_3625	Benzodiazepine	Nervous System	Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.	Influenza virus	Influenza A/California/7/2009		qRT-PCR	Decrease (50 %)	Approved, Investigational	27654301
DrugRepV_3649	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Influenza virus	California/07/2009		Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3650	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Influenza virus	Brisbane/10/2007		Luciferase assay	Decrease (50 %)	NA	21270170
DrugRepV_3670	2-phenyl-4-(1,1,2,2-tetrafluoroethyl)-3H-1,5-benzodiazepine	NA	NA	Influenza virus	Goose/Qinghai/59/05		Luciferase reporter assay	Decrease (15 %)	NA	21270170
DrugRepV_3696	BCX4430	NA	Ebola virus	Influenza virus	pH1N1		RT-PCR	Decrease (50 %)	Investigational	24590073
DrugRepV_4091	Bafilomycin A1	Antibiotics	NA	Influenza virus	A/turkey/ England/50-92/91		Inhibition assay	Decrease (50 %)	Experimental	26069727
DrugRepV_4095	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	Influenza virus	A/turkey/ England/50-92/91		Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4098	Omeprazole	Alimentary Tract and Metabolism	Duodenal ulcers | Benign gastric ulcers | Gastroesophageal reflux disease (GERD) | Heartburn and other symptoms associated with GERD	Influenza virus	A/turkey/ England/50-92/91		Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4102	Esomeprazole	Alimentary Tract and Metabolism	Acid-reflux disorders (GERD) and peptic ulcer disease	Influenza virus	A/turkey/ England/50-92/91		Inhibition assay	Decrease (50 %)	Approved	26069727
DrugRepV_4511	(1S,2R,5S)-5-{4-amino-1H-imidazo[4,5-c]pyridin-1-yl}-4-fluoro-3-(hydroxymethyl)cyclopent-3-ene-1,2-diol	NA	NA	Influenza virus	NA		NA	Decrease (50 %)	NA	30385162
DrugRepV_4515	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Influenza virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_4516	Zanamivir	Antiinfectives For Systemic Use	Influenza virus	Influenza virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_4517	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_4518	Amantadine	Nervous System	Influenza and Parkinson Disease	Influenza virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_5389	Quinacrine	NA	Malaria | Giardiasis | Cutaneous leishmaniasis | Management of malignant effusions	Influenza virus	NA		NA	Decrease (50 %)	Investigational	31307979
DrugRepV_5418	Regorafenib	Antineoplastic and Immunomodulating Agents	Metastatic colorectal cancer (CRC)	Influenza virus	WSN		WST-1 assay	Decrease (50 %)	Approved	30883607
DrugRepV_5419	Sorafenib	Antineoplastic and Immunomodulating Agents	Hepatocellular carcinoma | Renal cell carcinoma	Influenza virus	WSN		WST-1 assay	Decrease (50 %)	Approved, Investigational	30883607
DrugRepV_5430	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	A/Puerto Rico/8/34 (PR8)		Plaque reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	31244822
DrugRepV_5431	Gallium nitrate	NA	NA	Influenza virus	A/Puerto Rico/8/34 (PR8)		Plaque reduction assay	Decrease (50 %)	Approved, Investigational	31244822
DrugRepV_5432	Ketotifen	Respiratory System	Atopic asthma | Conjunctivitis	Influenza virus	A/Puerto Rico/8/34 (PR8)		Plaque reduction assay	Decrease (50 %)	Approved	31244822
DrugRepV_5433	Dextromethorphan	Respiratory System	Cough	Influenza virus	A/Puerto Rico/8/34 (PR8)		Plaque reduction assay	Decrease (50 %)	Approved	31244822
DrugRepV_5434	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	pdm09A/Mexico/InDRE4487/2009		Plaque reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	31244822
DrugRepV_5435	Gallium nitrate	NA	NA	Influenza virus	pdm09A/Mexico/InDRE4487/2009		Plaque reduction assay	Decrease (50 %)	Approved, Investigational	31244822
DrugRepV_5436	Ketotifen	Respiratory System	Atopic asthma | Conjunctivitis	Influenza virus	pdm09A/Mexico/InDRE4487/2009		Plaque reduction assay	Decrease (50 %)	Approved	31244822
DrugRepV_5437	Dextromethorphan	Respiratory System	Cough	Influenza virus	pdm09A/Mexico/InDRE4487/2009		Plaque reduction assay	Decrease (50 %)	Approved	31244822
DrugRepV_5438	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	A/Victoria/36/2011		Plaque reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	31244822
DrugRepV_5439	Gallium nitrate	NA	NA	Influenza virus	A/Victoria/36/2011		Plaque reduction assay	Decrease (50 %)	Approved, Investigational	31244822
DrugRepV_5440	Ketotifen	Respiratory System	Atopic asthma | Conjunctivitis	Influenza virus	A/Victoria/36/2011		Plaque reduction assay	Decrease (50 %)	Approved	31244822
DrugRepV_5441	Dextromethorphan	Respiratory System	Cough	Influenza virus	A/Victoria/36/2011		Plaque reduction assay	Decrease (50 %)	Approved	31244822
DrugRepV_5442	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	A/Puerto Rico/8/34 (PR8)		Virus inhibition assay	Decrease (5.3 log)	Approved, Investigational, Vet approved	31244822
DrugRepV_5443	Gallium nitrate	NA	NA	Influenza virus	A/Puerto Rico/8/34 (PR8)		Virus inhibition assay	Decrease (5.3 log)	Approved, Investigational	31244822
DrugRepV_5444	Dextromethorphan	Respiratory System	Cough	Influenza virus	A/Puerto Rico/8/34 (PR8)		Virus inhibition assay	Decrease (5.7 log)	Approved	31244822
DrugRepV_5445	Ketotifen	Respiratory System	Atopic asthma | Conjunctivitis	Influenza virus	A/Puerto Rico/8/34 (PR8)		Virus inhibition assay	Decrease (5.8 log)	Approved	31244822
DrugRepV_5446	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	pdm09A/Mexico/InDRE4487/2009		Virus inhibition assay	Decrease (6.2 log)	Approved, Investigational, Vet approved	31244822
DrugRepV_5447	Gallium nitrate	NA	NA	Influenza virus	pdm09A/Mexico/InDRE4487/2009		Virus inhibition assay	Decrease (5.2 log)	Approved, Investigational	31244822
DrugRepV_5448	Dextromethorphan	Respiratory System	Cough	Influenza virus	pdm09A/Mexico/InDRE4487/2009		Virus inhibition assay	Decrease (5.5 log)	Approved	31244822
DrugRepV_5449	Ketotifen	Respiratory System	Atopic asthma | Conjunctivitis	Influenza virus	pdm09A/Mexico/InDRE4487/2009		Virus inhibition assay	Decrease (5.1 log)	Approved	31244822
DrugRepV_5450	Naltrexone	Nervous System	Alcohol dependence	Influenza virus	A/Victoria/36/2011		Virus inhibition assay	Decrease (5.5 log)	Approved, Investigational, Vet approved	31244822
DrugRepV_5451	Gallium nitrate	NA	NA	Influenza virus	A/Victoria/36/2011		Virus inhibition assay	Decrease (5.5 log)	Approved, Investigational	31244822
DrugRepV_5452	Dextromethorphan	Respiratory System	Cough	Influenza virus	A/Victoria/36/2011		Virus inhibition assay	Decrease (5.3 log)	Approved	31244822
DrugRepV_5453	Ketotifen	Respiratory System	Atopic asthma | Conjunctivitis	Influenza virus	A/Victoria/36/2011		Virus inhibition assay	Decrease (5.5 log)	Approved	31244822
DrugRepV_5457	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	A/Sydney/185/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5458	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	A/Singapore/TT1275/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5459	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	A/Sydney/158/2016		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5460	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	A/Victoria/2500/2016		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5461	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	A/Malaysia/2/2014		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5462	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	A/Victoria/1031/2010		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5463	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	A/Victoria/1035/2010		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5464	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	A/Victoria/92/2012		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5465	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	A/Malaysia/22/2013		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5466	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	A/Sydney/236/2014		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5467	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	B/South Australia/2/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5468	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	B/Canberra/1/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5469	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	B/South Australia/5/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5470	Tizoxanide	Antiparasitic products, Insectisides and Repellents	Crytosporidiosis and Giardiasis	Influenza virus	B/Perth/136/2015		Focus forming reduction assay	Decrease (50 %)	Approved, Investigational, Vet approved	28986103
DrugRepV_5471	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	FPV/H7N7		Plaque assay	No significant effect (2.5 Log)	Approved	29990517
DrugRepV_5472	Trametinib	Antineoplastic and Immunomodulating Agents	Thyroid cancer	Influenza virus	Mallard/H5N1		Plaque assay	No significant effect (2 Log)	Approved	29990517
DrugRepV_5506	Anthralin	NA	Psoriasis	Influenza virus	H1N1		TCID50 assay	Decrease (99 %)	Approved	32132985
DrugRepV_5507	Anthralin	NA	Psoriasis	Influenza virus	H1N1		TCID50 assay	Decrease (99 %)	Approved	32132985
DrugRepV_5525	Papaverine	Genito Urinary System and Sex Hormones	Impotence | Vasospasms	Influenza virus	A/WSN/33		Plaque assay	Decrease (50 %)	Approved, Investigational	31896588
DrugRepV_5526	Papaverine	Genito Urinary System and Sex Hormones	Impotence | Vasospasms	Influenza virus	B/Lee/40		Plaque assay	Decrease (50 %)	Approved, Investigational	31896588
DrugRepV_5527	Papaverine	Genito Urinary System and Sex Hormones	Impotence | Vasospasms	Influenza virus	A/Udorn/72		Plaque assay	Decrease (50 %)	Approved, Investigational	31896588
DrugRepV_5528	Papaverine	Genito Urinary System and Sex Hormones	Impotence | Vasospasms	Influenza virus	A/Equine/2/MIAMI/1/63		Plaque assay	Decrease (50 %)	Approved, Investigational	31896588
DrugRepV_5529	Papaverine	Genito Urinary System and Sex Hormones	Impotence | Vasospasms	Influenza virus	A/PR/8/34		Plaque assay	Decrease (50 %)	Approved, Investigational	31896588
DrugRepV_5530	Papaverine	Genito Urinary System and Sex Hormones	Impotence | Vasospasms	Influenza virus	B/MD/59		Plaque assay	Decrease (50 %)	Approved, Investigational	31896588
DrugRepV_7908	Antimycin A	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7909	Brequinar	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Experimental	31941776
DrugRepV_7910	6-Azauridine	NA	Cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7911	Azaribine	NA	Psoriasis	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7912	Pyrazofurin	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7913	AVN-944	NA	Cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7914	Mycophenolate mofetil	NA	Organ rejection (immunosuppressants)	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Approved, Investigational	31941776
DrugRepV_7915	Mycophenolic acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Approved	31941776
DrugRepV_7916	Obatoclax	Anticancer	Leukemia | Myelofibrosis | Hodgkin's Lymphoma | Mantle-Cell Lymphoma	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7917	OSU-03012	Anticancer	Brain cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7918	Antimycin A	NA	NA	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7919	Brequinar	NA	NA	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	Experimental	31941776
DrugRepV_7920	6-Azauridine	NA	Cancer	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7921	Azaribine	NA	Psoriasis	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7922	Pyrazofurin	NA	NA	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7923	AVN-944	NA	Cancer	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7924	Mycophenolate mofetil	NA	Organ rejection (immunosuppressants)	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	Approved, Investigational	31941776
DrugRepV_7925	Mycophenolic acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Influenza virus	B/Brisbane/60/08		MTT assay	Decrease (50 %)	Approved	31941776
DrugRepV_7926	Antimycin A	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7927	Brequinar	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Experimental	31941776
DrugRepV_7928	6-Azauridine	NA	Cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7929	Azaribine	NA	Psoriasis	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7930	Pyrazofurin	NA	NA	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7931	AVN-944	NA	Cancer	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7932	Mycophenolate mofetil	NA	Organ rejection (immunosuppressants)	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Approved, Investigational	31941776
DrugRepV_7933	Mycophenolic acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Influenza virus	A/Puerto Rico/8/34		MTT assay	Decrease (50 %)	Approved	31941776
DrugRepV_7934	Antimycin A	NA	NA	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7935	Brequinar	NA	NA	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	Experimental	31941776
DrugRepV_7936	6-Azauridine	NA	Cancer	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7937	Azaribine	NA	Psoriasis	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7938	Pyrazofurin	NA	NA	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	NA	31941776
DrugRepV_7939	AVN-944	NA	Cancer	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	Investigational	31941776
DrugRepV_7940	Mycophenolate mofetil	NA	Organ rejection (immunosuppressants)	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	Approved, Investigational	31941776
DrugRepV_7941	Mycophenolic acid	Antineoplastic and Immunomodulating Agents	Organ rejection (immunosuppressants)	Influenza virus	A/New Caledonia/20/1999		MTT assay	Decrease (50 %)	Approved	31941776
DrugRepV_8452	Itraconazole	Antiinfectives For Systemic Use	Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis)	Influenza virus	PR8M		MTT assay	Decrease (50 %)	Approved, Investigational	30866762
DrugRepV_8453	Itraconazole	Antiinfectives For Systemic Use	Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis)	Influenza virus	PR8M		MTT assay	Decrease (90 %)	Approved, Investigational	30866762
DrugRepV_8454	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Influenza virus	PR8M		MTT assay	Decrease (50 %)	Approved, Investigational, Vet approved	30866762
DrugRepV_8455	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Influenza virus	PR8M		MTT assay	Decrease (90 %)	Approved, Investigational, Vet approved	30866762